Evidence map›Paper›PMID 29259752›Full record

ArticleACS medicinal chemistry letters2017

Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol.

Nada Abla, Sridevi Bashyam, Susan A Charman, Béatrice Greco, Philip Hewitt, Maria Belén Jiménez-Díaz, Kasiram Katneni, Holger Kubas, Didier Picard, Yuvaraj Sambandan and 6 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nada AblaMerck Global Health Institute, Ares Trading S.A., a subsidiary of Merck KGaA (Darmstadt, Germany), Coinsins 1267, Switzerland.
Sridevi BashyamSyngene International, Bangalore 560 099, India.
Susan A CharmanMMV Expert Scientific Advisory Committee, Centre for Drug Candidate Optimisation, Monash University, Parkville, VIC 3052, Australia.
Béatrice GrecoMerck Global Health Institute, Ares Trading S.A., a subsidiary of Merck KGaA (Darmstadt, Germany), Coinsins 1267, Switzerland.
Philip HewittMerck, KGaA, Darmstadt 64293, Germany.
Maria Belén Jiménez-DíazGSK, 28760 Tres Cantos, Spain.
Kasiram KatneniMMV Expert Scientific Advisory Committee, Centre for Drug Candidate Optimisation, Monash University, Parkville, VIC 3052, Australia.
Holger KubasMerck, KGaA, Darmstadt 64293, Germany.
Didier PicardDépartement de Biologie Cellulaire, Université de Genève, Sciences III, 30 quai Ernest-Ansermet, 1211 Genève 4, Switzerland.
Yuvaraj SambandanSyngene International, Bangalore 560 099, India.
Laura SanzGSK, 28760 Tres Cantos, Spain.
Dennis SmithMMV Expert Scientific Advisory Committee, Centre for Drug Candidate Optimisation, Monash University, Parkville, VIC 3052, Australia.
Tai WangDépartement de Biologie Cellulaire, Université de Genève, Sciences III, 30 quai Ernest-Ansermet, 1211 Genève 4, Switzerland.
Paul WillisMedicines for Malaria Venture, 1215 Geneva, Switzerland.
Sergio WittlinSwiss TPH, Basel 4051, Switzerland.
Thomas SpangenbergMerck Global Health Institute, Ares Trading S.A., a subsidiary of Merck KGaA (Darmstadt, Germany), Coinsins 1267, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With ∼429,000 deaths in 2016, malaria remains a major infectious disease where the need to treat the fever symptoms, but also to provide relevant post-treatment prophylaxis, is of major importance. An azepanylcarbazole amino alcohol is disclosed with a long- and fast-acting in vivo antiplasmodial efficacy and meets numerous attributes of a desired post-treatment chemoprophylactic antimalarial agent. The synthesis, the parasitological characterization, and the animal pharmacokinetics and pharmacodynamics of this compound are presented along with a proposed target.

Identifiers

PMID29259752
PMCPMC5733276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.